ESR2 and intrahepatic cholestasis: We validated the changes in 5 out of 7 core putative targets in the treatment of DCHT for ANIT-induced intrahepatic cholestasis, with the exception of estrogen receptor (ESR) 1 and 2 (ESR1 and ESR2) because they are more associated with intrahepatic cholestasis during pregnancy (Song et al., 2014).